<DOC>
	<DOC>NCT02681991</DOC>
	<brief_summary>Renamezin Capsule (an oral adsorbent) lowers indoxyl sulfate levels in patient with chronic renal failure. 120 patients with chronic renal failure(baseline serum creatinine:1.5-5.0mg/dl). Renamezin is administered 6.0mg/day. The treatment period is 2 months. The change in serum indoxyl sulfate will be evaluated.</brief_summary>
	<brief_title>Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>1. patients spontaneously written consent to participate in this clinical trial 2. men and women over age of 19 3. predialysis patients with chronic renal failure stage patient for 3 months and patients for holding the stable state in serum creatinine 1.5mg/dl 5.0mg/dl 4. patients who were no noticeable change for 12weeks before screening and are expected to change is not needed during therapy in the therapy of chronic renal failure(medication and dose related, diet therapy) 1. patients with passes through the digestive tract disorders 2. patients with uncontrolled constipation symptoms 3. patients suffering from digestive tract ulcers and esophageal varices 4. patients with untreated severe hypertension (DBP ≥ 120mmHg) 5. patients hospitalized with angina pectoris, cardiovascular disease or diagnosed with serious arrhythmia or cerebrovascular disease within 6 months 6. patients with hepatic impairment (2 times greater than the upper limit of normal levels of AST, ALT) 7. subjects with dependency on alcohol 8. patients with current infections 9. pregnant women, nursing mothers 10. Patients with a possibility of pregnancy (However, negative case can be registered) 11. patients participating in another clinical trial in addition to the current clinical trial 12. Patient who do not fit the clinical trial participation the legal and mentally</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>